Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-22-096534
Filing Date
2022-08-31
Accepted
2022-08-31 16:05:35
Documents
2
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm2224392d1_sc13ga.htm SC 13G/A 53705
2 EXHIBIT 99.2 tm2224392d1_ex99-2.htm EX-99.2 18183
  Complete submission text file 0001104659-22-096534.txt   73413
Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Filed by) CIK: 0001673852 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Subject) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91525 | Film No.: 221218009
SIC: 2834 Pharmaceutical Preparations